Welcome to our dedicated page for Outlook Therapeutics news (Ticker: OTLK), a resource for investors and traders seeking the latest updates and insights on Outlook Therapeutics stock.
Outlook Therapeutics, Inc. develops and commercializes ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab for retina diseases, including wet age-related macular degeneration. Company news commonly covers the product’s European Commission and MHRA marketing authorizations, commercial launch activity in Germany, Austria and the UK, and U.S. regulatory communications involving the biologics license application pathway for neovascular AMD.
Updates also include capital-structure actions used to fund operations, such as public offerings, registered direct offerings, warrants, convertible-note amendments and note financing. Governance and shareholder-approval matters appear in connection with securities issuance and authorized-share requirements.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Outlook Therapeutics (Nasdaq: OTLK) announces participation of Russ Trenary, CEO, and Glen Olsheim, Executive Director, in a live fireside chat at the H.C. Wainwright BioConnect Investor Conference on May 2, 2023, at 2:00 PM ET. The event will spotlight their work on ONS-5010, the first FDA-approved ophthalmic formulation of bevacizumab targeting retinal conditions like wet AMD. A live video webcast will be available on the company's website, with a replay accessible for 90 days. Outlook is also preparing for the PDUFA goal date of August 29, 2023, concerning their BLA submission for ONS-5010. They have partnered with AmerisourceBergen for commercial logistics related to this product.